Risks associated with Mycophenolate Mofetil and COVID-19
Immunosuppressive drugs like MMF can lead to increased susceptibility of
patients to infections. Patients taking MMF as part of their treatment
plan are considered high risk and advised to undertake increased
precautionary measures against COVID-19. Renal, cardiac and hepatic
transplant patients taking MMF are considered vulnerable and should be
managed with facilities staffed with adequate resources with support
therapy and treatment to reduce mortality associated with COVID-19.
Moreover, it can also lead to development of lymphoma in solid organ
transplant patients [18-19].